UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
NCT00083551
Completed
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/21/2015
Locations: University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
NCT00409188
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Saint Edward Mercy Medical Center, Fort Smith, Arkansas +294 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
NCT01495572
Terminated
Background: - Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can fight tumors. Before treatment with PBL, chemotherapy is given to destroy existing white blood cells so that the new cells can survive and attack the tumors. After PBL treatment, aldesleukin is given to help the new cells grow. Researchers want to see if special whit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
NCT00450801
Completed
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2015
Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida
Conditions: Lymphoma
Register for Updates
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
NCT00203372
Completed
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2015
Locations: UCLA Medical Center, Los Angeles, California +8 locations
Conditions: Breast Cancer
Register for Updates
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
NCT00923195
Completed
Background: * Melanoma antigen recognized by T-cells (MART-1) and gp100 are two genes found in melanoma cells. An experimental procedure developed for treating patients with advanced melanoma uses these genes and a type of virus to make special cells called anti-MART-1 and anti-gp100 cells, which are designed to destroy the patient's tumor. The cells are created in the laboratory using the patient's own tumor cells or blood cells. * The procedure also uses one of two vaccines-the anti-MART-1 pe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Melanoma, Skin Cancer
Register for Updates
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
NCT00610311
Terminated
Background: * gp100 is a protein that is often found in melanoma tumors. * An experimental procedure developed for treating patients with melanoma uses anti-gp100 cells designed to destroy their tumors. The anti-gp100 cells are created in the laboratory using the patient's own tumor cells or blood cells. * The treatment procedure also uses a vaccine called plaque purified canarypox vector (ALVAC) gp100, made from a virus that ordinarily infects canaries and is modified to carry a copy of the gp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
NCT00612222
Terminated
Background: * Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. * An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make special cells called anti-MART-1 F5 cells that are designed to destroy the patient's tumor. These cells are created in the laboratory using the patient's own tumor cells or blood cells. * The treatment procedure also uses a vaccine called plaque purified canarypox v... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Melanoma, Skin Cancer
Register for Updates
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
NCT00924287
Terminated
Background: * Human epidermal growth factor receptor-2 (Her-2) is a gene found in both normal cells and cancer cells. Extra copies of the gene (overexpression) can cause too many Her-2 proteins (receptors) to appear on the cell surface and cause tumors to grow. * An experimental procedure developed for treating patients with cancer uses blood cells found in their tumors or bloodstream. The cells are genetically modified using the anti-Her-2 gene and a type of virus. The modified cells (anti-Her... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Cancer
Register for Updates
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCT01273181
Terminated
Background: - MAGE-A3/12 is a type of protein commonly found on certain types of cancer cells, particularly in metastatic cancer. Researchers have developed a process to take lymphocytes (white blood cells) from cancer patients, modify them in the laboratory to target cancer cells that contain MAGE-A3/12, and return them to the patient to help attack and kill the cancer cells. These modified white blood cells are an experimental treatment, but researchers are interested in determining their saf... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
Register for Updates
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
NCT00704938
Terminated
RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells. Vaccines made from a gene modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Giving gene-modified lymphocytes together with high-dose aldesleukin and vaccine therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland
Conditions: Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00096382
Completed
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies, such as cellular adoptive immunotherapy, work in different ways to stimulate the immune system and stop tumor cells from growing. Autologous stem cell transplant may be able to replace immune cells that were destroyed by chemotherapy and radiatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2015
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland +1 locations
Conditions: Melanoma (Skin)
Register for Updates